Lucid Diagnostics, Inc.

Lucid Diagnostics develops and commercializes the EsoGuard DNA test, a non-invasive next-generation sequencing diagnostic designed to detect esophageal precancer (Barrett's esophagus) in office-based settings without endoscopy. The company targets high-risk populations, including patients with chronic reflux symptoms and occupational cohorts such as firefighters (who have a 62% increased risk of esophageal cancer). EsoGuard enables early detection of precancerous changes, allowing clinicians to intervene before disease progression to esophageal adenocarcinoma. The test leverages targeted NGS technology to identify molecular markers of Barrett's esophagus and dysplasia. Lucid partners with gastroenterology practices, primary care clinics, and occupational health programs to integrate the test into routine screening workflows. The company serves patients and healthcare systems across the United States. Regulatory status and specific FDA clearance details are not explicitly stated in available content, though the product is actively marketed and endorsed by board-certified gastroenterologists and surgeons at major medical institutions. Manufacturing and laboratory processing capabilities are referenced through clinical partnerships and patient testimonials. The company is publicly traded and provides investor updates on financial and operational performance.